APP markets new cancer drug
SCHAUMBURG - Fresenius Kabi Pharmaceuticals Holding Inc. announced that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. Anastrozole is therapeutically equivalent to the reference-listed drug Arimidex, which is currently marketed by the innovator AstraZeneca. APP will market Anastrozole in 1 mg tablets.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.